A BILL 
To amend the Federal Food, Drug, and Cosmetic Act, with 
respect to eligibility for approval of a subsequent generic 
drug, to remove the barrier to that approval posed by 
the 180-day exclusivity period afforded to a first generic 
applicant that has not yet received final approval, and 
for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Bringing Low-cost Op-
4
tions and Competition while Keeping Incentives for New 
5
Generics Act of 2019’’ or the ‘‘BLOCKING Act of 2019’’. 
6
22:43 Feb 11, 2019
H938
2 
•HR 938 IH
SEC. 2. CHANGE CONDITIONS OF FIRST GENERIC EXCLU-
1
SIVITY TO SPUR ACCESS AND COMPETITION. 
2
Section 505(j)(5)(B)(iv) of the Federal Food, Drug, 
3
and Cosmetic Act (21 U.S.C. 355(j)(5)(B)(iv)) is amend-
4
ed— 
5
(1) in subclause (I), by striking ‘‘180 days 
6
after’’ and all that follows through the period at the 
7
end and inserting the following: ‘‘180 days after the 
8
earlier of— 
9
‘‘(aa) the date of the first com-
10
mercial marketing of the drug (includ-
11
ing the commercial marketing of the 
12
listed drug) by any first applicant; or 
13
‘‘(bb) the applicable date speci-
14
fied in subclause (III).’’; and 
15
(2) by adding at the end the following new sub-
16
clause: 
17
‘‘(III) APPLICABLE DATE.—The appli-
18
cable date specified in this subclause, with 
19
respect to an application for a drug de-
20
scribed in subclause (I), is the date on 
21
which each of the following conditions is 
22
first met: 
23
‘‘(aa) The approval of such an 
24
application could be made effective, 
25
but for the eligibility of a first appli-
26
22:43 Feb 11, 2019
H938
3 
•HR 938 IH
cant for 180-day exclusivity under 
1
this clause. 
2
‘‘(bb) At least 30 months have 
3
passed since the date of submission of 
4
an application for the drug by at least 
5
one first applicant. 
6
‘‘(cc) Approval of an application 
7
for the drug submitted by at least one 
8
first applicant is not precluded under 
9
clause (iii). 
10
‘‘(dd) No application for the drug 
11
submitted by any first applicant is ap-
12
proved at the time the conditions 
13
under items (aa), (bb), and (cc) are 
14
all met, regardless of whether such an 
15
application 
is 
subsequently 
ap-
16
proved.’’. 
17
Æ 
22:43 Feb 11, 2019
H938
